MaaT Pharma SA is planning to move its lead microbiome-based ecosystem therapy, MaaT013, into late-stage Phase III studies following promising top-line data from a Phase II study, HERACLES, in patients with acute graft-versus host disease (aGvHD). The data is the latest from microbiome-based companies using novel treatment approaches for a broad brush of indications.
GvHD Could Yield To MaaT Pharma's Microbiome-Based Ecosystem Therapies
Phase III Studies Planned
MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.

More from Clinical Trials
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from R&D
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.